1,840 Shares in The Chemours Company (NYSE:CC) Purchased by Brooklyn Investment Group

Brooklyn Investment Group acquired a new position in The Chemours Company (NYSE:CC) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 1,840 shares of the specialty chemicals company’s stock, valued at approximately $37,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC lifted its holdings in Chemours by 3.5% in the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock valued at $368,650,000 after purchasing an additional 618,361 shares in the last quarter. Marshall Wace LLP lifted its holdings in Chemours by 23.8% in the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock valued at $158,213,000 after purchasing an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC lifted its holdings in Chemours by 54.6% in the 2nd quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after purchasing an additional 1,220,967 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its holdings in Chemours by 6.8% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 2,824,301 shares of the specialty chemicals company’s stock valued at $63,744,000 after purchasing an additional 178,625 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Chemours by 26.7% in the 2nd quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company’s stock valued at $40,896,000 after purchasing an additional 382,100 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Stock Down 0.4 %

CC opened at $21.74 on Friday. The firm has a 50 day moving average price of $19.65 and a 200 day moving average price of $21.39. The company has a market cap of $3.25 billion, a PE ratio of 43.64 and a beta of 1.75. The Chemours Company has a 1 year low of $15.10 and a 1 year high of $32.70. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. Sell-side analysts expect that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.60%. The ex-dividend date of this dividend is Friday, November 15th. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Chemours from $25.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th. The Goldman Sachs Group reduced their target price on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, September 3rd. UBS Group cut their price objective on shares of Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Barclays increased their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, BMO Capital Markets increased their price objective on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $24.88.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.